A lawyer for Pennsylvania urged seven justices of the Pa. Commonwealth Court yesterday to allow the state’s case against Johnson & Johnson’s subsidiary Janssen to proceed, saying that a judge had “wrongfully taken the case away from the jury” in 2010. Among the evidence presented was a 1999 letter from the FDA to Janssen stating “The materials and promotional messages Janssen has disseminated contain false and/or misleading information about the safety and effectiveness of Risperdal.” One month ago, a judge awarded $1.1 billion in damages to Arkansas for a similar case, argued by the same lawyers.
State Argues $150 Mil. Risperdal Suit Should Have Gone to Jury
Pennsylvania Court to Hear Appeal of Dismissed Risperdal Lawsuit
J&J Fined $1.1 Billion for Hidden Risks of Risperdal
J&J Tries, Fails to Squeeze Whistle Blower in Texas Risperdal Case
Justice Department Raises J&J Settlement to $1.8 Billion
J&J Settles Texas Medicaid Lawsuit for $158 Million
J & J to Pay More Than $1 Billion For Wrongful Marketing of Risperdal
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.